Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
- Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
- Novartis secures development and commercialization rights in North America, Europe, and Japan
- Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
- Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors
Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.
Under the terms of the agreement, Novartis will obtain the development and commercialization rights to tislelizumab in the United States, Canada, Mexico, the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan in exchange for an upfront payment of USD 650 million plus royalties and milestone payments. BeiGene will retain the rights to tislelizumab in China and other countries. The transaction has been approved by the Boards of Directors of both companies.
More than 7,700 patients have been enrolled in 15 potentially registration-enabling clinical trials with tislelizumab in a dozen indications, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma, gastric cancer and nasopharyngeal carcinoma. The first ex-China regulatory filing is expected in 2021. In addition, Novartis and BeiGene have identified multiple tislelizumab plus Novartis therapy combination clinical trial opportunities in solid tumors.
“Novartis has a bold ambition to reimagine medicine and find new cures for cancer and blood disorders. This agreement expands on our strategy as the only company pursuing four different approaches to treating cancer: targeted therapy, radioligand therapy, cell and gene therapy, and immunotherapy. No other company has this range of therapeutic approaches, and the opportunity to combine them to offer the best outcomes for each patient,” said Susanne Schaffert, PhD, President, Novartis Oncology. “We are excited about collaborating with BeiGene, a leading global biotechnology company with roots in China, to bring tislelizumab to patients around the world, and pair it with our extensive portfolio and pipeline to develop transformative combination therapies for patients.”
Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for certain patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma. In addition, BeiGene has filed three supplemental new drug applications for tislelizumab in China for first-line treatment of patients with advanced squamous NSCLC in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable HCC.
Closing of the transaction is subject to expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” “to develop,” “development,” “ambition,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for tislelizumab, or regarding potential future revenues from tislelizumab; or regarding the agreement to in-license tislelizumab from BeiGene in major markets outside of China. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the transaction described in this press release will be completed in the expected time frame, or at all. Neither is there any guarantee that the expected benefits and synergies from such transaction will be achieved in the expected timeframe, or at all. Nor can there be any guarantee that tislelizumab will be submitted or approved for sale in any market, or at any particular time. Neither can there be any guarantee that tislelizumab will be commercially successful in the future. In particular, our expectations regarding the transaction described in this press release and tislelizumab could be affected by, among other things, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
# # #
Novartis Media Relations
|Anja von Treskow||Julie Masow|
|Novartis External Communications||Novartis Oncology Communications|
|+41 79 392 86 97 (mobile)||+1 862 579 8456 (mobile)|
|Novartis US External Communications|
|+1 646 438 4335|
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Mandalay Resources Corporation Announces Recent Drilling Results for Costerfield’s Youle Deposit, Highlighting Further High-Grade Gold Depth Extensions26.1.2021 13:30:00 CET | Press release
TORONTO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to provide an update on the Youle extension project at Costerfield, highlighting the delineation of the previously reported southern domain, and the discovery of a new high-grade extension to the northern trend of Youle. Youle Drilling Highlights Drill holes convey lateral continuity of current mine development area, linking to previously reported southern domain (Figure 4): 264.1 g/t gold and 19.7% antimony over a true width of 0.23 m in BC162; and94.7 g/t gold and 16.4% antimony over a true width of 0.05 m in BC158. New high-grade results north of Youle extending at depth: 345.1 g/t gold and 19.7% antimony over a true width of 0.11 m in BC166W1;316.1 g/t gold and 0.1% antimony over a true width of 0.22 m in BC167; and 142.0 g/t gold and 0.0% antimony over a true width of 0.07 m in BC157. Note: Significant drill composites are given in Tables 1 an
INTELEX SECURES UNINTERRUPTED POSITION AS A LEADER IN GREEN QUADRANT FOR EHS SOFTWARE 202126.1.2021 13:05:00 CET | Press release
Independent analyst research firm recognizes Intelex for transformative connected EHSQ ecosystem approach and core EHS and Quality Management application strengths TORONTO, CANADA, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Intelex Technologies, ULC, a leading global provider of SaaS-based Environmental, Health, Safety and Quality (EHSQ) management software, today announced it has been classified a Leader by independent analyst firm, Verdantix, in its 2021 Green Quadrant for EHS Software for a fourth consecutive time. Since first participating in the Green Quadrant EHS Software Report in 2015, Intelex has consistently maintained a strong foothold in the Leaders quadrant. In the 2021 benchmark report, Verdantix recognizes Intelex for its differentiation in expanding from EHSQ software to deliver connected digital ecosystem solutions, highlighting the company’s “transformative approach to centralize asset, equipment, and workforce information for real-time data analysis and safety culture improve
Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus26.1.2021 13:00:00 CET | Press release
Press Release Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the “British variant”), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU). The virus variant was labelled “Variant of Concern 202012/01” by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronavirus variants. This variant has also been identified in the U.S. in several states. Based on the previous positive pre-clinical test results with stenoparib as a treatment of SARS-CoV-2, announced on 26 August 2020, Allarity Therapeutics will now test the sim
RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS26.1.2021 11:30:00 CET | Press release
Auction date2021-01-26Maturity2024Tendered volume, SEK mln1000 +/- 1000Offered volume, SEK mln0Volume bought, SEK mln0Number of bids0Number of accepted bids0 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln0000Volume bought, SEK mln0000Number of bids0000Number of accepted bids0000Average yield, %----Lowest accepted yield, %----Highest yield, %----Accepted at lowest yield, %---- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln0000Volume bought, SEK mln0000Number of bids0000Number of accepted bids0000Average yield, %----Lowest accepted yield, %----Highest yield, %----Accepted at lowest yield, %----
RCS users to grow 294% by 2024, driving new revenue for mobile operators26.1.2021 11:04:00 CET | Press release
New report from Mobilesquared and Interop Technologies indicates that MNOs stand to gain a 240% revenue uplift over the forecast period by launching a native RCS solution LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rich messaging is becoming a key platform connecting brands with consumers, joining the list of mainstream marketing channels alongside TV, the internet, and social media, according to the findings of a new report by business messaging intelligence experts, Mobilesquared. By the end of 2024 there will be more than 3 billion RCS users, representing an unparalleled growth rate of 294%. This high rate of growth is set to position RCS as the largest enhanced messaging platform globally and provide new revenue opportunities for mobile operators. The report, Safeguarding Revenue from A2P Messaging, published by Mobilesquared in partnership with Interop Technologies, highlights how RCS’ growth will help operators remain at the centre of mobile messaging. The only business messaging c
RESULT OF RIKSBANK CERTIFICATE SALE26.1.2021 10:15:00 CET | Press release
AuctionAuction resultsAuction date2021-01-26Start date2021-01-27Maturity date2021-02-03Interest rate, %0.00Offered volume, SEK bn380.0Total bid amount, SEK bn1521.4Accepted volume, SEK bn380.0Number of bids15Percentage alloted, %24.977
Maxihost Enables Next Generation Workloads with Powerful Ampere Processors26.1.2021 10:00:00 CET | Press release
Collaboration brings high-performance Arm®-based microprocessors to Maxihost Bare Metal Cloud platform. SÃO PAULO, Brazil, Jan. 26, 2021 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=1iQ1BYMsZnun4xtGOTo7wF3uhR8iIyf3bFyT4GTQ5QNQKa8JTUZ1c3bOW2q5LvxkDvC7KwzrRHKVBbUaiu37zkCIYmJYQkua-fhz7qQH99M= Ampere® Computing, a developer of high-performance Arm®-based microprocessors for cloud and edge servers, and Maxihost, an innovative global provider of Bare Metal Cloud, are working together to enable on-demand bare metal access to Ampere’s energy-efficient, high-performance processors for the first time in South America. Access is also enabled for Maxihost clients in New York and Miami and will soon be available for clients in Los Angeles, Chicago, Dallas, Santiago and Sydney. Ampere processors deliver excellent total cost of ownership (TCO) value, high-performance compute, high-memory capacity, and rich I/O to address a broad range of workloads including application servers, cont